Work

Synthesis and evaluation of Oncrasin based radiotracers for oncology

Year: 2018
Type: dissertation
Abstract: KRAS mutation status in cancer is an important contributing factor to development of cancerous tissue, with the mutation occurring in an estimated 1/3 of all cases of cancer, resulting in an aggressive phenotype. Development of a radiotracer based on the synthetic lethal Oncrasin-1 molecule was envisioned as a possible means of developing an imaging agent to identify and stage KRAS mutant tumours, with the potential to stratify patients into different treatment groups based off this. Small molecule drugs are routinely used as radiotracer leads, however, the mechanism of action of this compound is not well understood as it was identified in a synthetic lethal screen for KRAS. Despite the unknown mechanism of action, the ability of these compounds to differentiate between cancer types shows real promise as an imaging diagnostic to aid in the differentiation between cancer treatment groups and improve treatment outcomes. To evaluate if this class of compound as a potential radiotracer, 7 fluorine containing analogues and derivatives of Oncrasin-1 were synthesized along with the parent compound to evaluate their potencies relative to the parent Oncrasin-1 and investigate their potential to differentiate between tumours harbouring different kRAS mutation status. In this evaluation, potency is used as a surrogate marker for binding affinity, as development of radiotracers is a costly and resource intensive process. Along with the cold standards, precursors of the radiotracers were synthesized, initially through an attempted iodonium salt intermediate, however, it was discovered through the course of this work that the indole scaffold is incompatible with the oxidising conditions required to produce the hypervalent iodonium salt. Synthesis of an alternative pinacol boronic acid ester was therefore undertaken and precursors for 3 radiotracers were successfully produced, with a fourth radiotracer production being achieved through a post labelling reduction reaction. Radiosynthesis was successfully undertaken of 18F labelled KAM001, KAM002, KAM003 and KAM011, with decay corrected radiochemical yields between 10-18% for these radiotracers. 18F labelled KAM011 was successfully synthesized through a post labelling reduction of 18F labelled KAM001 resulting in a decay corrected radiochemical yield of 12%. Biological evaluation of compounds in colon cancer cell lines indicated improved potency and selectivity between the parent and two compounds tested in KRAS mutant cell lines and wild type cell lines, however, the potency testing in BRAF mutant cell lines gave inconclusive toxicity and cell cycle analysis. Preliminary radiotracer uptake studies were carried out in colon cancer cell lines and showed poor differentiation between KRAS mutant and KRAS wild type cell lines with the 18F KAM001 radiotracer. Further development in the understanding of these compounds since the beginning of this project indicate that the family of compounds likely have multiple mechanisms of action, with one of the molecular targets being identified as the enzyme Sulfotransferase 1A1, also known as SULT1A1, which has been shown to be abnormally expressed in many types of cancer, including breast cancer. Identification of SULT1A1 expression in breast tissue can be a marker of cancer, as upregulation of this enzyme is abnormal in this type of tissue. Identification of the presence of this enzyme also has potential value as a prognostic indicator as it has been associated with abnormal metabolism of drugs and has been linked to improved Tamoxifen response in oestrogen sensitive cancers. Potency testing of the compounds showed good differentiation between the commonly used MCF-7 and MDA-MB-231 breast cancer cell lines, with cell cycle analysis showing different trends depending on the substitution pattern in sensitive MCF-7 cell line but no discernible trend in the insensitive MDA-MB-231 cell line. Preliminary radiotracer uptake assays showed differentiation between the cell lines with the 18F labelled KAM001 and even better differentiation with the 18F labelled KAM011 tracer. Subsequent stability and metabolism studies indicated good tracer stability for the 18F labelled KAM011 tracer for the imaging period required. Imaging studies with the 18F labelled KAM011 tracer showed good differentiation of tumours, with high tumour to muscle ratio found in sensitive tumours and visually apparent internalization of radiotracer. In insensitive MDA-MB-231 cell lines a low tumour to muscle ratio was observed, with a build-up of radiotracer around the peripheral tissue still showing the tumour visually. This thesis outlines the methods and procedures of synthesizing cold standards, precursors, and radiotracers which were developed from the Oncrasin molecule. These molecules have been used in biological evaluation and imaging studies which have shown improved potency over the parent compound in cell culture as well as the ability to effectively differentiate between tumour types in both in vivo and in vitro models, with the potential for stratification of patient groups pending further investigation.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2912063906
Cites: 121
Cited by:
Related to: 9